Spyre Therapeutics Management
Management criteria checks 0/4
Spyre Therapeutics' CEO is Cameron Turtle, appointed in Oct 2023, has a tenure of less than a year. total yearly compensation is $16.17M, comprised of 1.7% salary and 98.3% bonuses, including company stock and options. directly owns 1.47% of the company’s shares, worth €17.87M. The average tenure of the management team and the board of directors is 0.9 years and 1.2 years respectively.
Key information
Cameron Turtle
Chief executive officer
US$16.2m
Total compensation
| CEO salary percentage | 1.7% |
| CEO tenure | less than a year |
| CEO ownership | 1.5% |
| Management average tenure | less than a year |
| Board average tenure | 1.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$186m |
| Mar 31 2024 | n/a | n/a | -US$364m |
| Dec 31 2023 | US$16m | US$273k | -US$339m |
Compensation vs Market: Cameron's total compensation ($USD16.17M) is above average for companies of similar size in the German market ($USD1.62M).
Compensation vs Earnings: Insufficient data to compare Cameron's compensation with company performance.
CEO
Cameron Turtle (34 yo)
less than a year
Tenure
US$16,174,660
Compensation
Dr. Cameron Turtle, D.Phil. & Ph D., joined Spyre Therapeutics, Inc. as Chief Operating Officer in June 2023 and served until November 28, 2023, and was appointed as Spyre Therapeutics, Inc. Chief Executiv...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$16.17m | 1.47% $ 17.9m | |
| Chief Financial Officer | less than a year | US$7.55m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | less than a year | US$6.93m | 0% $ 0 | |
| Senior Vice President of Operations | no data | no data | no data | |
| Chief Technical Officer | less than a year | no data | no data | |
| Vice President of Finance & Investor Relations | no data | no data | no data | |
| Vice President of Quality & Compliance | no data | no data | no data | |
| Senior Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Senior Vice President of People | no data | no data | no data | |
| Consultant | 1.3yrs | US$865.79k | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data |
0.9yrs
Average Tenure
44yo
Average Age
Experienced Management: 3920's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | US$16.17m | 1.47% $ 17.9m | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Independent Chairman of the Board | less than a year | US$433.57k | 0.068% $ 824.5k | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.9yrs | no data | no data | |
| Independent Director | 1.2yrs | US$658.43k | 0.80% $ 9.7m | |
| Independent Director | less than a year | no data | 0% $ 0 | |
| Independent Director | less than a year | US$434.38k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$660.78k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$661.28k | 0.80% $ 9.7m |
1.2yrs
Average Tenure
44yo
Average Age
Experienced Board: 3920's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.